We offer a broad range of services to support innovators and the NHS in generating and utilising real world evidence. We have invested in our team to expand our capacity and expertise and ensure we are able to deliver impactful evaluations to support downstream adoption and spread.
Our offerings include:
Early stage feasibility studies
- Lean Assessment
- Headroom analysis
- Value proposition testing
Service evaluation
- Pathway mapping and redesign
- Observational studies
- Comparative effectiveness research
- Data collection and management
- Mixed methods approaches
Health economic modelling and analyses
- Cost-effectiveness models
- Budget impact models
- Network meta-analyses
- Statistical analyses
Environmental impact analyses
Through these services we are able to support the real world adoption and scale-up of innovative products, helping to demonstrate their value within the NHS. Our work enables innovators and healthcare organisations to demonstrate the impact of innovation, build cases for adoption and spread and improve outcomes. Current real world evaluations in our portfolio include:
- myAsthma from my mhealth a digital solution designed to support healthcare providers and patients using asthma biologics (respiratory care)
- Care for MDD from Otsuka Pharmaceutical Ltd – a digital therapeutic for people with mild to moderate depression (mental health)
- Tympa platform from Tympa Health – an integrated platform for audiology assessment and treatment (primary care/community).
- Hailie smart inhaler from Helicon Health: A smart inhaler designed to enhance patient adherence to inhaler usage (Respiratory Care).
- EchoGo from Ultromics Ltd – an AI platform (cardiology).